Daré Bioscience, Inc.
Price Action
Technical Summary
CONSOLIDATINGDaré Bioscience, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 47), showing significant lag compared to the market leaders. Earnings growth of 58% provides fundamental context to the price action. Investors should exercise caution due to high volatility (95% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.05 | -0.03% | BELOW |
| 50 SMA | $2.27 | -9.76% | BELOW |
| 100 SMA | $2.00 | +2.40% | ABOVE |
| 150 SMA | $1.99 | +3.22% | ABOVE |
| 200 SMA | $1.99 | +3.07% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is DARE in an uptrend right now?
DARE has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is DARE overbought or oversold?
DARE's RSI (14) is 48. The stock is in neutral territory, neither overbought nor oversold.
Is DARE outperforming the market?
DARE has a Relative Strength (RS) Rating of 47 out of 99. DARE is currently lagging the broader market.
Where is DARE in its 52-week range?
DARE is trading at $2.05, which is 22% of its 52-week high ($9.19) and 10% above its 52-week low ($1.27).
How volatile is DARE?
DARE has a Beta of 0.84 and 52-week volatility of 95%. It's less volatile than the S&P 500 - generally more stable.